AtaiBeckley Inc.
Subsidiary of Eli Lilly (LLY)
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | 5-HT2A receptorSmall molecule | Major Depressive Disorder Treatment-Resistant Depression | |
| Phase 2 | Serotonergic system (MDMA-class entactogen)Small molecule | Social Anxiety Disorder | |
| Phase 2 | 5-HT2A receptorSmall molecule | Major Depressive Disorder Treatment-Resistant Depression |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (4)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $1.7M | $28M | $169M | $33M | report ↗ |
View 3 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | $0.9M | $17M | $43M | $30M | report ↗ |
| 2025-Q2 | $0.7M | $11M | $62M | $28M | report ↗ |
| 2025-Q1 | $1.6M | $11M | $58M | $26M | report ↗ |
Annual history (3 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $4.1M | $53M | $85M | $165M | report ↗ |
AtaiBeckley reported full-year 2025 revenue of $4.09M, up 1219.4% YoY, with R&D spend of $53.06M, down 4.3% YoY. Cash and equivalents were $85.3M, and the company reported a net loss of $660.05M.
Management expects existing cash to fund operations into 2029, covering planned topline readouts from both Phase 3 pivotal studies. BPL-003 Phase 3 initiation remains on track for Q2 2026 following a successful End of Phase 2 meeting with the FDA, VLS-01 Phase 2 Elumina topline data are anticipated in H2 2026, and the exploratory Phase 2a trial of EMP-01 in social anxiety disorder met its primary safety and tolerability objective with clinically meaningful efficacy improvements. Key events included the November 2025 strategic combination with Beckley Psytech, U.S. redomiciliation, and inclusion in the NASDAQ Biotechnology Index.